Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers
Business Wire India Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from the landmark MINDACT study will be shared at the 2021 American…